Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CARAMBA

Financiado

Cerrado

SLAMF7 CAR T cells prepared by Sleeping Beauty gene transfer for immunotherapy o...

SLAMF7 CAR T cells prepared by Sleeping Beauty gene transfer for immunotherapy of multiple myeloma a rare hematologic disease CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong deman... ver más

30/06/2023

KLINIKUM DER BAYER...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

UNIVERSITAETSKLINIKUM WUERZBURG KLINIKUM DER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-06-30

SC1-PM-08-2017: New therapies for rare diseases

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

KLINIKUM DER BAYERISCHEN JUL...

2.40M€ | Lider

UNISR

N.D. | Participante

OSR

748.13K€ | Participante

ARTTIC

152.49K€ | Participante

Proyectos interesantes

Exh-Res-CART

Medical Technol...

Data Science

161K€ Cerrado

INCITE

Medical Technol...

Data Science

4M€ Cerrado

CNS2023-143983

Medical Technol...

Data Science

200K€ Cerrado

RYC2018-024442-I

Medical Technol...

Cancer Treatmen...

309K€ Cerrado

EUIN2013-51221

Medical Technol...

Data Science

15K€ Cerrado

EURE-CART

Medical Technol...

Data Science

6M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 67 meses Fecha Inicio: 2017-11-22
Fecha Fin: 2023-06-30

Líder del proyecto

UNIVERSITAETSKLINIKUM WUERZBURG KLINIKUM DER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand by patients, their families and caregivers for a curative myeloma treatment. The CARAMBA investigators will conduct a phase I/II clinical trial of immunotherapy with patient-derived T cells that are engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7. SLAMF7 is uniformly expressed on all myeloma cells in every patient, and SLAMF7 CAR-T cells will be equally effective in women and men. The efficacy and safety of SLAMF7 CAR-T cells has been validated by the coordinator in comprehensive pre-clinical testing which highlighted their unprecedented curative potential. SLAMF7 CAR-T cells have received an orphan designation for the indication multiple myeloma by the EC. The successful conduct, rapid and complete recruitment into the clinical trial is ensured by participation of 4 clinical myeloma centres of excellence in 4 EU member states, and the largest myeloma patient advocacy group in Europe, MPE. The SME partners in CARAMBA are prepared to develop the SLAMF7 CAR product all the way to market authorization. CAR-T cell therapy has been recognized as a ‘Breakthrough Therapy’ and clinical proof-of-concept obtained with CD19 CAR-T cells in leukemia and lymphoma. CARAMBA is building on novel and proprietary, cutting-edge CAR technologies including virus-free Sleeping Beauty CAR gene-transfer from DNA minicircles which substantially reduces the cost of CAR-T cell manufacturing, making it an economically viable and sustainable medicinal product. We are confident, that if funded, CARAMBA will accomplish its objective to establish the role of CAR-T cell therapy as a therapeutically effective, commercially attractive and socioeconomically desirable treatment in myeloma and other rare diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores